Trial site
Urology Clinics of North Texas
Dallas, Texas 75231, United StatesNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 13 trials
- Early phase 11 trial
- Phase 21 trial
- Status
- Active, not recruiting8 trials
- Recruiting6 trials
- Completed3 trials
- Lead sponsor
- Janssen Research & Development, LLC4 trials
- Clarity Pharmaceuticals Ltd2 trials
- ORIC Pharmaceuticals2 trials
- PROCEPT BioRobotics2 trials
- Astellas Pharma Global Development, Inc.1 trial
- and 6 more
Running trials
Recruiting
WATER IV PCa (AS Sub-study)
NCT07650448· PROCEPT BioRobotics· Source
Contact: Jacquelyn Ward
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248· Phase 3· ORIC Pharmaceuticals· Source
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677· Phase 2· Tyra Biosciences, Inc· Source
Contact: Gina Risdall
Active, not recruiting
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847· Phase 3· Clarity Pharmaceuticals Ltd· Source
Active, not recruiting
WATER IV Prostate Cancer
NCT06651632· PROCEPT BioRobotics· Source
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830· Phase 3· Clarity Pharmaceuticals Ltd· Source
Contact: Alexander Parker, MD
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868· Phase 1· Aura Biosciences· Source
Recruiting
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421· Phase 1· ORIC Pharmaceuticals· Source
Contact: ORIC Clinical
Recruiting
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114· Phase 1· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Active, not recruiting
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317· Phase 3· Pfizer· Source
Active, not recruiting
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT01436968· Phase 3· Candel Therapeutics, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error